Abstract Background Neoadjuvant treatment for hormone receptor (HR)-positive breast cancer remains limited, particularly for tumours that are insensitive to neoadjuvant chemotherapy. This study aims to compare the efficacy of neoadjuvant endocrine therapy combined with CDK4/6 inhibitors to that of traditional neoadjuvant chemotherapy. Patients and methods A total of 49 patients receiving neoadjuvant endocrine therapy plus CDK4/6 inhibitors and 210 receiving neoadjuvant chemotherapy were enrolled. Magnetic resonance imaging (MRI) was performed to assess tumor responses every 2-3 cycles of treatment. Propensity score matching (PSM) was performed to balance baseline characteristics. Results Both before and after PSM, the objective response rate (ORR) in the endocrine therapy group was comparable to that of the traditional chemotherapy group. After matching, the ORR was 64.6% (95% CI: 49.5%-77.8%) in the endocrine group and 56.3% (95% CI: 41.2%-70.5%) in the chemotherapy group (p = 0.532). A higher proportion of patients in the endocrine group achieved to pathological complete or near-complete response (Miller-Payne grades 4-5, 13.5% vs. 10.4%) and post-treatment Ki67 5%, indicating a potential long-term benefit. Patients with ≥30% regression in maximal tumor diameter after 2 cycles of chemotherapy were considered chemotherapy-sensitive. Among patients with tumours less sensitive to chemotherapy, sequential treatment with neoadjuvant endocrine therapy plus CDK4/6 inhibitors significantly improved ORR (61.8% vs. 32.4%, p = 0.028), and was associated with greater Ki67 reduction and improve Miller-Payne grades. Conclusion Neoadjuvant endocrine therapy is a promising alternative for HR-positive breast cancer, especially for patients with poor response to chemotherapy.
Zhang et al. (Tue,) studied this question.